GENETAC

pharmaceutical preparations for the treatment of degenerative disorders and diseases, genetic disorders and diseases, and disorders and diseases caused by transcriptional dysregulation; therapeutic pharmaceuticals for the treatment of degenerative disorders and diseases, genetic disorders and diseases, and disorders and diseases caused by transcriptional dysregulation; small molecule therapies for the treatment of degenerative disorders and diseases, genetic disorders and diseases, and disorders and diseases caused by transcriptional dysregulation, all of the foregoing related to therapies that target nucleic acids and modulate gene expression

pharmaceutical research and products development for the treatment of degenerative disorders and diseases, genetic disorders and diseases, and disorders and diseases caused by transcriptional dysregulation; research and development of therapeutics for the treatment of degenerative disorders and diseases, genetic disorders and diseases, and disorders and diseases caused by transcriptional dysregulation; research and development in the field of small molecule therapeutics; scientific research for medical purposes in the field of degenerative disorders and diseases, genetic disorders and diseases, and disorders and diseases caused by transcriptional dysregulation; medical and scientific research in the field of pharmaceuticals, all of the foregoing related to therapies that target nucleic acids and modulate gene expression